

Michael J Elman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1305752/michael-j-elman-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

6,030
citations

29
h-index

60
g-index

60
ext. papers

7,082
ext. citations

6.3
avg, IF

4.98
L-index

#	Paper	IF	Citations
51	Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2021 , 139, 725-733	3.9	3
50	Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT: Age-Related Eye Disease Study 2: 10-Year Follow-On Study. <i>Ophthalmology</i> , 2021 , 128, 100-109	7.3	22
49	Re: Yu et al.: Home Monitoring of Age-Related Macular Degeneration: Real-World Utility of the ForeseeHome Device for Detection of Neovascularization. <i>Ophthalmology Retina</i> , 2021 , 5, e1	3.8	
48	Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
47	Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). <i>Ophthalmology</i> , 2020 , 127, 1201-1210	7.3	27
46	Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19. <i>Ophthalmology Retina</i> , 2020 , 4, 3-12	3.8	8
45	Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2. <i>Acta Ophthalmologica</i> , 2019 , 97, e998-e1005	3.7	15
44	Advances in the treatment of diabetic retinopathy. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 107417	3.2	27
43	Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. <i>Ophthalmology</i> , 2019 , 126, 261-273	7.3	19
42	Treatment of Geographic Atrophy with Intravitreal Sirolimus: The Age-Related Eye Disease Study 2 Ancillary Study. <i>Ophthalmology Retina</i> , 2018 , 2, 441-450	3.8	15
41	Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. <i>Ophthalmology</i> , 2018 , 125, 1054-1063	7.3	22
40	Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. <i>Ophthalmology</i> , 2018 , 125, 1913-1928	7.3	71
39	Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2018 , 136, 1138-1148	3.9	165
38	Fellow Eye Anti-VEGF Effect in Retinopathy of Prematurity. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018 , 49, e102-e104	1.4	7
37	Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion. <i>Ophthalmology Retina</i> , 2017 , 1, 413-420	3.8	8
36	EFFECTIVENESS OF DIFFERENT MONITORING MODALITIES IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Home Study, Report Number 3. <i>Retina</i> , 2016 , 36, 1542-7	3.6	13
35	Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. <i>Ophthalmology</i> , 2016 , 123, 1716-1721	7.3	33

34	Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2016 , 134, 127-34	3.9	42
33	Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. <i>New England Journal of Medicine</i> , 2015 , 372, 1193-203	59.2	937
32	Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. <i>Ophthalmology</i> , 2015 , 122, 375-81	7.3	251
31	Topical nepafenec in eyes with noncentral diabetic macular edema. <i>Retina</i> , 2015 , 35, 944-56	3.6	55
30	Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2015 , 133, 888-96	3.9	25
29	Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2137-2146	27.4	423
28	Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. <i>Ophthalmology</i> , 2014 , 121, 535-44	7.3	126
27	Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. <i>JAMA Ophthalmology</i> , 2014 , 132, 142-9	3.9	254
26	Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOME Monitoring of the Eye (HOME) study design - HOME Study report number 1. <i>Contemporary Clinical Trials</i> , 2014 , 37, 294-300	2.3	40
25	Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. <i>Ophthalmology</i> , 2014 , 121, 67-71	7.3	121
24	Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. <i>JAMA Ophthalmology</i> , 2013 , 131, 843-50	3.9	96
23	Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. <i>Ophthalmology</i> , 2012 , 119, 2312-8	7.3	304
22	Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14. <i>JAMA Ophthalmology</i> , 2012 , 130, 1517-24		23
21	Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. <i>Ophthalmology</i> , 2011 , 118, 609-14	7.3	433
20	Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. <i>Ophthalmology</i> , 2010 , 117, 1064-1077.e35	7.3	1041
19	Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. <i>JAMA Ophthalmology</i> , 2009 , 127, 132-40		83
18	Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. <i>JAMA Ophthalmology</i> , 2009 , 127, 1581-3		119
17	Patterns of referral of retinal patients for low vision intervention in the anti-VEGF era. <i>Retina</i> , 2009 , 29, 1036-9	3.6	4

16	Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. <i>American Journal of Ophthalmology</i> , 2008 , 145, 894-901	4.9	82
15	A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. <i>Ophthalmology</i> , 2007 , 114, 1860-7	7.3	380
14	Endogenous Fusarium endophthalmitis in a patient with acute lymphocytic leukemia. <i>American Journal of Ophthalmology</i> , 1994 , 117, 363-8	4.9	29
13	Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri. <i>Neurosurgery</i> , 1992 , 30, 391-5	3.2	79
12	Systemic associations of retinal vein occlusion. <i>International Ophthalmology Clinics</i> , 1991 , 31, 15-22	1.7	10
11	The effect of age and initial visual acuity on the systemic and visual prognosis of central retinal vein occlusion. <i>Australian and New Zealand Journal of Ophthalmology</i> , 1991 , 19, 118-22		9
10	Modified optic nerve decompression in patients with functioning lumboperitoneal shunts and progressive visual loss. <i>Ophthalmology</i> , 1991 , 98, 1449-53	7.3	80
9	The natural course of central retinal vein occlusion. <i>American Journal of Ophthalmology</i> , 1990 , 110, 118-239		141
8	The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. <i>Ophthalmology</i> , 1990 , 97, 1543-8	7.3	98
7	Intraoperative massive suprachoroidal hemorrhage during pars plana vitrectomy. <i>Ophthalmology</i> , 1990 , 97, 1114-9	7.3	43
6	The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Photocoagulation Study. The Macular Photocoagulation Study Group. <i>Ophthalmology</i> , 1989 , 96, 1526-34	7.3	63
5	A new modified vitreoretinal surgical approach in the management of massive suprachoroidal hemorrhage. <i>Ophthalmology</i> , 1989 , 96, 793-800	7.3	48
4	Transient Severe Visual Loss After Panretinal Photocoagulation. <i>American Journal of Ophthalmology</i> , 1988 , 106, 298-306	4.9	27
3	SKIN NECROSIS FOLLOWING FLUORESCEIN EXTRAVASATION. <i>Retina</i> , 1987 , 7, 89-93	3.6	19
2	The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. <i>Ophthalmology</i> , 1986 , 93, 224-30	7.3	60
1	Galactokinase activity in patients with idiopathic cataracts. <i>Ophthalmology</i> , 1986 , 93, 210-5	7.3	10